Eidos Therapeutics (EIDX) Short Interest Ratio & Short Volume

Short interest is the volume of Eidos Therapeutics shares that have been sold short but have not yet been covered or closed out. As of December 31st, traders have sold 495,600 shares of EIDX short. 3.67% of Eidos Therapeutics' shares are currently sold short. Learn More on Eidos Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EIDX shares currently have a short interest ratio of 3.0. Learn More on Eidos Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 3.67% of Eidos Therapeutics' floating shares are currently sold short.

Eidos Therapeutics saw a decline in short interest in December. As of December 31st, there was short interest totaling 495,600 shares, a decline of 1.2% from the previous total of 501,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Eidos Therapeutics currently has issued a total of 38,873,000 shares. Some of Eidos Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Eidos Therapeutics currently has a public float of 13,500,000 shares.

3.67% of Eidos Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Eidos Therapeutics: Organon & Co. (4.28%), BridgeBio Pharma, Inc. (10.29%), Madrigal Pharmaceuticals, Inc. (16.89%), Nuvalent, Inc. (20.22%), Alpine Immune Sciences, Inc. (8.05%), Perrigo Company plc (2.85%), Alkermes plc (8.48%), Blueprint Medicines Co. (7.14%), CymaBay Therapeutics, Inc. (5.10%), Ultragenyx Pharmaceutical Inc. (4.76%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($6.95 billion), Aon plc ($4.44 billion), Analog Devices, Inc. ($4.13 billion), Snap Inc. ($3.12 billion), Peloton Interactive, Inc. ($2.68 billion), Moderna, Inc. ($2.60 billion), The Clorox Company ($2.47 billion), The Kroger Co. ($2.32 billion), International Flavors & Fragrances Inc. ($2.21 billion), and Altice USA, Inc. ($1.94 billion). View all of the most shorted stocks.

Short selling EIDX is an investing strategy that aims to generate trading profit from Eidos Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Eidos Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of EIDX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EIDX, twice per month. The most recent reporting period available is December, 31 2020.